Royalty Pharma generated Portfolio Receipts of 874000000 in Q4 2025, up 18%, with Royalty Receipts of 856000000 and net income attributable to Royalty Pharma plc of 214000000.

Royalty Pharma delivered strong third-quarter 2025 results with double-digit growth in both Royalty Receipts and Portfolio Receipts, primarily driven by Voranigo, Tremfya, and the cystic fibrosis franchise. The company also significantly increased its Capital Deployment to $1.0 billion for the quarter, expanding its portfolio with three innovative therapies, and raised its full-year 2025 guidance for Portfolio Receipts.

Royalty Pharma delivered excellent second quarter 2025 results, with Portfolio Receipts growing 20% to $727 million and Royalty Receipts increasing 11% to $672 million. The company also completed the acquisition of its external manager, becoming an integrated company, and announced a significant funding agreement with Revolution Medicines. Royalty Pharma repurchased $1 billion of its Class A ordinary shares in the first half of the year, demonstrating a strong fundamental outlook.

Royalty Pharma delivered a robust first quarter in 2025, with Portfolio Receipts growing 17% to $839 million and Royalty Receipts increasing 12% to $788 million. The company repurchased $723 million in Class A ordinary shares and raised its full-year 2025 guidance for Portfolio Receipts.

Royalty Pharma saw strong 12% growth in royalty receipts, primarily driven by Evrysdi, the cystic fibrosis franchise, Trelegy, and Xtandi. However, overall revenue declined slightly due to a high comparison base from milestone payments received in the prior year. The company also launched a $3 billion share buyback program to enhance shareholder value.

Royalty Pharma reported a strong third quarter with a 15% increase in Portfolio Receipts to $735 million. The company also increased its capital deployment to $1.2 billion and raised its full-year guidance for Portfolio Receipts to $2.75 to $2.8 billion.

Royalty Pharma reported a 12% increase in Portfolio Receipts, reaching $608 million, and an 11% increase in Royalty Receipts. The company also raised its full-year 2024 guidance for Portfolio Receipts to $2,700 to $2,775 million. Capital deployment was approximately $2 billion in 2024.

Royalty Pharma's first quarter 2024 saw a 14% increase in Royalty Receipts, driven by royalties on Evrysdi, Trelegy, and the cystic fibrosis franchise. However, Portfolio Receipts decreased due to a significant Biohaven-related milestone payment in Q1 2023. The company confirmed its full-year 2024 guidance for Portfolio Receipts and continues to deploy capital, including acquiring royalties on Sanofi's frexalimab.

Royalty Pharma reported a decrease in Portfolio Receipts by 31% to $736 million for Q4 2023, which was due to accelerated Biohaven payments in Q4 2022. Royalty receipts increased by 10%, driven by cystic fibrosis franchise, Trelegy and Evrysdi, and the addition of new royalties on Spinraza.

Royalty Pharma reported a 7% increase in Adjusted Cash Receipts to $637 million, driven by strong performances of the CF franchise and Trelegy, and the addition of Spinraza. The company also announced transactions of up to $3.8 billion year-to-date, including $2.1 billion in upfront payments and raised its 2023 guidance for Adjusted Cash Receipts to $2,950 to $3,000 million.

Royalty Pharma reported strong financial performance in Q2 2023, with Adjusted Cash Receipts increasing by 4% to $545 million. The company raised its full-year 2023 guidance for Adjusted Cash Receipts to $2.900 to $2.975 billion. Transactions of up to $1.7 billion were announced year-to-date, including $659 million in upfront payments.

Royalty Pharma reported strong Q1 2023 results, with total income and other revenues increasing by 22% to $684 million. Adjusted Cash Receipts increased by 87% to $1,131 million, driven by the Zavzpret milestone and strong portfolio performance. The company reaffirmed its 2023 Adjusted Cash Receipts guidance of $2,850 to $2,950 million.

Royalty Pharma reported a strong Q4 2022, marked by a 96% increase in Adjusted Cash Receipts to $1,064 million and a 99% increase in Adjusted EBITDA to $983 million. The company executed nine deals for potentially transformative therapies and provided full year 2023 guidance, excluding new transactions.

Royalty Pharma reported a 15% increase in net cash provided by operating activities, reaching $539 million, and a 2% increase in Adjusted Cash Receipts, totaling $597 million. The company announced transactions of up to $3.0 billion year-to-date, including $1.7 billion in upfront payments. Royalty Pharma increased its full-year 2022 guidance for Adjusted Cash Receipts to $2,750 to $2,800 million.

Royalty Pharma reported a decrease in total income and other revenues by 3% to $536 million. However, Adjusted Cash Receipts increased by 10% to $524 million, driven by the cystic fibrosis franchise, Xtandi, and Tremfya. The company also announced transactions of up to $2.5 billion year-to-date and raised full-year 2022 guidance for Adjusted Cash Receipts to $2,275 to $2,350 million.

Royalty Pharma reported a decrease in net cash provided by operating activities to $460 million, while total income and other revenues decreased 2% to $562 million. However, Adjusted Cash Receipts increased 15% to $605 million and Adjusted EBITDA grew 15% to $556 million. The company reaffirmed its 2022 Adjusted Cash Receipts guidance of $2,225 million to $2,300 million.

Royalty Pharma reported strong Q4 and full year 2021 results, with Adjusted Cash Receipts growing by 12% in Q4 and 18% for the full year. The company also announced transactions of $3.0 billion in 2021 and introduced 2022 Adjusted Cash Receipts guidance of $2,225 to $2,300 million.

Royalty Pharma reported a 9% increase in total income and other revenues to $586 million, driven by strong portfolio performance, new royalty acquisitions, and a one-time payment related to Soliqua. Adjusted Cash Receipts increased 24% to $587 million, and Adjusted Cash Flow grew 12% to $441 million.

Royalty Pharma reported a 9% increase in total income and other revenues to $555 million. Adjusted Cash Receipts increased 3% to $475 million, and Adjusted Cash Flow grew 16% to $429 million. The company also raised its full-year 2021 guidance for Adjusted Cash Receipts to $2,080 to $2,120 million.

Royalty Pharma reported a 14% increase in total income and other revenues to $573 million, driven by growth from the cystic fibrosis franchise. Adjusted Cash Receipts increased 37% to $524 million and Adjusted Cash Flow grew 37% to $409 million.

Royalty Pharma's Q4 2020 results showed an 18% increase in net cash provided by operating activities and a 9% increase in Adjusted Cash Receipts. The company also announced $2.4 billion in acquisitions for 2020 and increased its outlook for 2020-2025 Adjusted Cash Receipts CAGR to 7%-10%.

Royalty Pharma reported a strong third quarter with a 17% increase in net cash from operating activities and a 12% increase in adjusted cash receipts. The company also increased its 2020 guidance for adjusted cash receipts and announced $2.3 billion in new acquisitions for the year.

Royalty Pharma announced its intention to offer senior unsecured notes in a private offering to repay existing debt and for general corporate purposes.